Takuya Kato

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Photodynamic Therapy

Fluorescent Probe

Top Venues

Molecular cancer therapeutics

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Teruki Kobayashi, Kazuhiro Noma, Seitaro Nishimura, Takuya Kato, Noriyuki Nishiwaki, Toshiaki Ohara, Tomoyoshi Kunitomo, Kento Kawasaki, Masaaki Akai, Satoshi Komoto, Hajime Kashima, Satoru Kikuchi, Hiroshi Tazawa, Yasuhiro Shirakawa, Peter C Black, Hisataka Kobayashi, Toshiyoshi Fujiwara
Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Patient-Derived Xenografts using a Humanized anti-Fibroblast Activation Protein Antibody. Molecular cancer therapeutics (2024)
Teruki Kobayashi, Kazuhiro Noma, Seitaro Nishimura, Takuya Kato, Noriyuki Nishiwaki, Toshiaki Ohara, Tomoyoshi Kunitomo, Kento Kawasaki, Masaaki Akai, Satoshi Komoto, Hajime Kashima, Satoru Kikuchi, Hiroshi Tazawa, Yasuhiro Shirakawa, Peter C Black, Hisataka Kobayashi, Toshiyoshi Fujiwara
Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Patient-Derived Xenografts Using a Humanized Anti-Fibroblast Activation Protein Antibody. Molecular cancer therapeutics 23 (7) (2024)
Hiroshi Fukushima, Aki Furusawa, Takuya Kato, Hiroaki Wakiyama, Seiichiro Takao, Shuhei Okuyama, Peter C Black, Hisataka Kobayashi
Intratumoral interleukin-15 improves efficacy of near-infrared photoimmunotherapy. Molecular cancer therapeutics (2023)
Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki F Inagaki, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter C Black, Hisataka Kobayashi
Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy. Cancer immunology research 10 (11) (2022)
Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki F Inagaki, Hiroaki Wakiyama, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter C Black, Hisataka Kobayashi
Near-Infrared Photoimmunotherapy Targeting Podoplanin-Expressing Cancer Cells and Cancer-Associated Fibroblasts. Molecular cancer therapeutics (2022)